Trium Capital LLP Astrazeneca PLC Transaction History

Trium Capital LLP

$801 Million
Q1 2025

A detailed history of Trium Capital LLP transactions in Astrazeneca PLC stock. As of the latest transaction made, Trium Capital LLP holds 102,641 shares of AZN stock, worth $7.23 Million. This represents 0.94% of its overall portfolio holdings.

Number of Shares

102,641

Holding current value

$7.23 Million

% of portfolio

0.94%

1 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2025 Apr 30, 2025	BUY	$65.37 - $77.96 $6.71 Million - $8 Million	102,641 New	102,641 $7.54 Million

Others Institutions Holding AZN

# of Institutions

1,427

Shares Held

504M

Call Options Held

10M

Put Options Held

3.14M

Price T Rowe Associates Inc Baltimore, MD

57.1M
Shares

$4.02 Billion
0.52% of portfolio
Primecap Management CO Pasadena, CA

40.7M
Shares

$2.86 Billion
2.53% of portfolio
Wellington Management Group LLP Boston, MA

35.6M
Shares

$2.51 Billion
0.52% of portfolio
Bank Of America Corp Charlotte, NC

31.8M
Shares

$2.24 Billion
0.19% of portfolio
Capital International Investors Los Angeles, CA

31.3M
Shares

$2.2 Billion
0.47% of portfolio

View Full List

About ASTRAZENECA PLC

Ticker AZN
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 3,099,020,032
Market Cap $218B
Description
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...

More about AZN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Trium Capital LLP, based on Form 13F filings with the SEC.

News

Stay updated on Trium Capital LLP with notifications on news.

Account